Collectionner le produit
Détails du produit
Synonyms
uPAR, PLAUR, CD87, MO3
Source
Human uPAR (23-114) Protein, His Tag (UPR-H52H8) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Tyr 114 (Accession # Q03405-1).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 12.4 kDa. The protein migrates as 14-17 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human uPAR (23-114) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC
The purity of Human uPAR (23-114) Protein, His Tag (Cat. No. UPR-H52H8) was greater than 90% as determined by SEC-HPLC.
Bioactivity-SPR
Human uPAR (23-114) Protein, His Tag(Cat. No. UPR-H52H8) immobilized on CM5 Chip can bind Human PLAU, His Tag (Cat. No. PLU-H5229) with an affinity constant of 6.08 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Urokinase plasminogen activator surface receptor
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
7 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
